DrugMonitor™ Anti-Elotuzumab Antibody (VS-1224-YC413) (CAT#: VS-1224-YC413)

Elotuzumab is a humanized IgG1 monoclonal antibody indicated for use with lenalidomide and dexamethasone in multiple myeloma treatment. The DrugMonitor™ Anti-Elotuzumab Antibody (VS-1224-YC413) is an anti-drug antibody (ADA) against Elotuzumab. This drug-based antibody is raised in mice immunized with the Elotuzumab. The anti-Elotuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Elotuzumab in samples.

Specific Inquiry
  • Size:
  • Conjugation:
  • Purity:
  • Datasheet
  • MSDS
  • COA

Specifications

  • Host Animal
  • Mouse
  • Specificity
  • Elotuzumab
  • Target
  • Elotuzumab
  • Immunogen
  • Elotuzumab
  • Type
  • Mouse IgG
  • Species Reactivity
  • Human
  • Purity
  • >95%
  • Purification
  • Protein G
  • Applications
  • ELISA, PK/PD, ADA control
  • Format
  • Liquid
  • Concentration
  • Batch-dependent
  • Buffer
  • PBS, pH 7.4
  • Preservative
  • No preservatives
  • Storage
  • Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
  • Generic name
  • Elotuzumab
  • Drug Weight
  • 148100.0 Da
  • Formula
  • C₆₄₇₆H₉₉₈₂N₁₇₁₄O₂₀₁₆S₄₂
  • Related Disease
  • Multiple myeloma treatment

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "elotuzumab"

Anti-SLAMF7 Recombinant Antibody (Elotuzumab)
Recombinant humanized antibody expressed in CHO binding to human SLAMF7/CD319. Elotuzumab is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.
Afuco™ Anti-SLAMF7 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-743)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human SLAMF7/CD319. It is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for VS-1224-YC413. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare